Hypocalcemia in a dialysis patient treated with deferasirox for iron overload.
Deferasirox is a new iron chelator approved recently for chelation therapy in iron-overloaded patients. It is considered safe and efficacious in most patients, but has not been tested formally in patients with end-stage renal disease. We report a case of a patient with end-stage renal disease secondary to sickle cell nephropathy who developed recurrent symptomatic hypocalcemia while on therapy and later reexposure with this medication for iron overload from long-term blood transfusions. This is the first case report of this complication with deferasirox therapy in a patient with end-stage renal disease.
Section of Nephrology, Yale University School of Medicine, New Haven, CT 06520-8029, USA.
Bushra
B
Yusuf
Peter
P
McPhedran
Ursula C
UC
Brewster
D000328:Adult; D000755:Anemia, Sickle Cell / Q000150:complications / Q000628:therapy; D001565:Benzoates / Q000009:adverse effects* / Q000627:therapeutic use; D000077588:Deferasirox; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D006996:Hypocalcemia / Q000139:chemically induced*; D007502:Iron Chelating Agents / Q000009:adverse effects* / Q000627:therapeutic use; D019190:Iron Overload / Q000188:drug therapy* / Q000209:etiology; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D065227:Transfusion Reaction; D014230:Triazoles / Q000009:adverse effects* / Q000627:therapeutic use
D001565:Benzoates; D007502:Iron Chelating Agents; D014230:Triazoles; D004921:Erythropoietin; D000077588:Deferasirox